Form 8-K - Current report:
SEC Accession No. 0001213900-25-055334
Filing Date
2025-06-18
Accepted
2025-06-17 19:16:04
Documents
14
Period of Report
2025-06-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0246111-8k_relmada.htm   iXBRL 8-K 28367
2 PRESS RELEASE ISSUED ON JUNE 17, 2025 ea024611101ex99-1_relmada.htm EX-99.1 17815
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2024
  Complete submission text file 0001213900-25-055334.txt   220416

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rlmd-20250617.xsd EX-101.SCH 3011
5 XBRL LABEL FILE rlmd-20250617_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE rlmd-20250617_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0246111-8k_relmada_htm.xml XML 3705
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 251054721
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)